Advances in systemic treatment for limited-stage SCLC have not progressed over the decades. However, more recent studies have suggested that adjuvant therapy with a high-affinity human IgG1 monoclonal ...

Consolidation durvalumab is underutilized in unresectable stage III NSCLC, with only 61.5% of eligible patients receiving it post-cCRT. Patients receiving durvalumab after cCRT show improved ...

Taiwan's defence ministry said on Tuesday it is watching the movements of a Chinese aircraft carrier and assessing China's military activities as security sources said Beijing could launch new war ...

However, there is currently no consensus on the standard of care for this population. Durvalumab, an immune checkpoint inhibitor, has shown promise for treating a wide range of cancers, and has been ...

Source: Getty Images Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder cancer, according to Thomas Powles, MBBS ...

For ticket holders with access needs there are disabled parking bays at Pacific Quay which can be used by members of the public if available. The BBC security team will always do their best to ...

PACIFIC helps put AZ back on the map after its much-anticipated MYSTIC trial failed to hit its primary endpoint earlier this year. MYSTIC studied the PD-L1 therapy of durvalumab in combination ...

However, there is currently no consensus on the standard of care for this population. Durvalumab, an immune checkpoint inhibitor, has shown promise for treating a wide range of cancers, and has been ...

Taiwan president kicks off Pacific tour with US stops, drawing anger from Beijing ...

A new trial finds that cetuximab outperforms durvalumab as a second-line treatment in these cases ...

前言肺癌是全球范围内导致癌症死亡的主要原因之一。非小细胞肺癌（NSCLC）占所有肺癌病例的80%-85%，其中约30%的NSCLC患者初诊时为Ⅲ期[1]。III期NSCLC具有高度的临床和病理异质性，可进一步分为ⅢA期、ⅢB期和ⅢC期，其5年生存率随 ...